Future Live announces that it has obtained the patent for enflog®, an important milestone that confirms the value of the research and development activities conducted by the company.
The patent was granted by virtue of the formulation’s originality and its functional uniqueness: enflog® is, in fact, composed of a precise set of enzymes selected and studied to act in synergy and with high specificity toward protein substrates of biological interest.
In particular, the enflog® enzymatic complex has demonstrated the ability to interact with the biofilm produced by certain bacteria, performing a targeted action both in preventing biofilm formation and in promoting its disruption.
This mechanism is particularly relevant because the biofilm acts as a protective barrier that can increase the resistance of microorganisms: its disruption makes the bacteria more exposed and thus potentially more susceptible to attack by any antibacterial agents.
Obtaining the patent represents a significant step in the company’s growth path, confirming its constant commitment to the research and development of innovative solutions based on solid scientific evidence.